NCT05351320View on ClinicalTrials.gov

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

May 30, 2026

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

WX-0593 Tablets

WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily

DRUG

chemotherapy

Platinum-based chemotherapy

RADIATION

Thoracic Radiation Therapy（TRT）

Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Jinming Yu

OTHER